MHRA Launches Program to Address Gaps in Women's Health Research
image

MHRA Launches Program to Address Gaps in Women's Health Research

By: Global Woman Leader Team | Tuesday, 17 November 2026

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new program to improve the evidence available on medicines and medical devices for women. The initiative aims to provide a better understanding of how the risks and benefits of medical treatments may vary for women.

Although women account for 51% of the population, gaps in medical research and treatment continue to affect their healthcare. Historically, women have been underrepresented in clinical studies, resulting in limited evidence on the safety and effectiveness of medicines and medical devices during pregnancy and across different stages of reproductive health.

There are also unmet needs related to conditions that affect women, conditions that affect women in different ways and conditions that affect women more. This MHRA review of all UK clinical trial applications submitted over the last five years (2019-2023) identified ongoing underrepresentation. Only 1.1% of trials represented pregnant women and 0.6% represented breastfeeding women. 

Key Highlights:

  • MHRA launches a program to address gaps in women's health research
  • Only 1.1% of UK clinical trials included pregnant women and 0.6% included breastfeeding women
  • The initiative aims to improve medical evidence, treatments and FemTech innovation

The Women's Health Program is designed to tackle these challenges and understand how improved data and scientific research can better represent the needs of women. 

Women’s Health Minister, Baroness Gillian Merron, said: “For too long, women’s health has been overlooked. More than half of our population is women, but women have been underrepresented in studies that have informed the development of medicines and devices that they use. That's not good enough and we're not going to put up with it.

“This new program is a welcome step. Together with our renewed Women’s Health Strategy, it will mean better evidence, better treatments, and a health system that listens to women and works for them.”

Lawrence Tallon, MHRA Chief Executive, said:  “Closing the gaps in our understanding of how the risks and benefits of medicines and medical devices differ for women is both a challenge and a huge opportunity. 

“Better evidence can help us understand where important differences exist, support researchers and innovators and create opportunities for healthcare that is better tailored to women’s needs.” 

Medicines and medical devices are complex, and factors such as biology, age, pregnancy and other health conditions can affect how people respond to them. The program will bring together patients, researchers, healthcare professionals, and industry to strengthen the evidence available, while maintaining our robust standards of safety, quality and effectiveness.   

Women’s health is also a major area for innovation. The UK’s rapidly growing FemTech sector already has an annual turnover of nearly £300 million, with technologies being developed across areas from reproductive health to long-term conditions and healthy ageing. 

By working with researchers and innovators early and building better evidence about how the benefits and risks of medicines may differ for women, the MHRA wants to foster an environment where promising new products can be developed and reach patients earlier. 

Naho Yamazaki, Deputy Director of Policy and Partnerships at the Health Research Authority, said:  “We welcome the MHRA’s Women’s Health Program and its ambition to strengthen the evidence base for women’s health. Ensuring that people who are under-represented in research are considered and included in clinical trials is essential if research is to generate evidence that is relevant to the populations who will ultimately use new medicines and treatments. 

“Our joint guidance with the MHRA on developing an Inclusion and Diversity Plan offers a practical framework to help researchers consider, from the earliest stages of study design, how their participant population can better reflect the people who may benefit from the research. This will help make sure those women, girls and those who are pregnant or breastfeeding are not left behind in research that is relevant to them. 

“The guidance, and the MHRA’s Women’s Health Program, will contribute to the important work being undertaken across the health and social care research sector to make studies more inclusive and representative, helping to ensure that the evidence generated better reflects diverse populations and supports efforts to reduce health inequalities.”

Michelle Riddalls OBE, CEO of PAGB, and The Consumer Healthcare Association, said: “It’s positive to see the MHRA’s new Women’s Health Program points to a clear focus on closing longstanding evidence gaps while supporting responsible innovation.

“Better evidence can help women make more informed choices as well as creating opportunities to widen access to appropriate treatments through the reclassification of medicines, supporting more women to manage their health through self-care. We welcome the MHRA’s ambition to ensure that the regulatory system continues to evolve with new evidence and supports appropriate innovation that can make a real difference to women’s health.

“In recent times we have seen both low‑dose Estradiol vaginal products and Estriol cream reclassified which have transformed access to Hormone Replacement Therapy (HRT) for thousands of women, positive examples of providing women with greater choice and more convenient access to treatments”

The development of the program has been informed by patients, involving input from the MHRA Patients and Public Community and by the focus group carried out by the Patients Association. This program marks the beginning of the wider initiative launched by the MHRA to confront health inequalities as noted in the recently published 2030 Strategy.

The Women’s Health Program has been initiated by the MHRA as a regulation contribution following the government effort to enhance women's health indicated in the updated Women’s Health Strategy for England within the respective domains in Scotland, Welsh and Northern Ireland.

The announcement will take place at the first-ever DIA-MHRA Global Summit that will take place on the 16th-17th of November in London as a key part of the London Life Sciences Week. This event is organized by the MHRA in cooperation with the DIA and gathered together international regulators, pharmaceutical industry leaders, scientists, healthcare community members as well as patient group representatives.

Latest Issues

Jenny Van Dam: Lifting Industry Standards through Purposeful Leadership


Most Viewed

🍪 Do you like Cookies?

We use cookies to ensure you get the best experience on our website. Read more...